A 28-year-old woman presented with "rosacea" of 2 years' duration for which her previous physician had prescribed daily use of triamcinolone 0.1% cream. She complained of swelling and a worsening situation of her rosacea each time she discontinued it. She went to visit another doctor who prescribed tacrolimus and crisaborole ointment to treat her. She insisted the prescription was making the symptoms worse. Increasing involvement of the face and suffering feelings were causing her significant pain. When she first came to our visit, she reported intermittent itching (Figure 1A) (peak pruritus was 6 of 10 on a numeric rating scale). She was given the hydroxychloroquine (0.2g twice daily), minocycline (50mg/d) and topical metronidazole gel for 2 weeks. However, the patient reported severe itching (peak pruritus was 9 of 10 on a numeric rating scale). Her face was more swollen and irritable (Figure 1B). Given the progressive disease, the ineffective routine plan and the patient's associated concern, we decided to pursue a more aggressive strategy. We were looking for a new anti-inflammatory drug. An article published on JAAD which referred to JAK/STAT signaling pathway contributing to multiple inflammatory dermatoses inspired us to treat her with JAK1/3 inhibitors tofacitinib after she had undertook blood routine examination, biochemistry analysis, coagulation function and chest CT to exclude severe infection, coagulation disorder, hepatic failure, renal disfunction and tuberculosis. Treatment with tofacitinib was initiated at a dosage of 5 mg twice daily. After 2 weeks symptoms relieved a lot, swelling on her face reduced (Figure 1C). The dosage was decreased to 5 mg/d for the next 2 weeks. As we can see, only perioral erythema remained and the patient reported middle itching (Figure 1D) (peak pruritus was 4 of 10 on a numeric rating scale. Then, the dosage was decreased to 5mg every other day for 2 weeks. She kept on using the topical metronidazole gel during the whole process. Finally, the skin lesions almost disappeared completely (Figure 1E) with occasionally itching (peak pruritus was 1 of 10 on a numeric rating scale and her mental health improved. Course of drug treatment suspended. She discontinued tofacitinib for 12 weeks without relapse of the eruption (Figure 1F). No adverse effects were detected.